Literature DB >> 2555094

Paraneoplastic subacute cerebellar degeneration in Hodgkin's disease. Report of three cases and review of the literature.

H P Schlake1, I W Husstedt, K H Grotemeyer, R Pötter.   

Abstract

12 cases of paraneoplastic cerebellar degeneration with Hodgkin's disease have so far been reported. Three additional patients (Stage II-IA/IIA/IIIB) are presented. Although CT and MR-imaging (MRI) revealed a marked cortical atrophy of the cerebellum, there was no evidence of direct brain involvement. After irradiation and chemotherapy all patients showed a complete remission. There was no evidence of primary disease after an observation period of 3/2/5 years. Cerebellar symptoms also showed a partial remission. As compared to the literature, our treatment appears to be more favorable, probably due to the fact, that therapy was more aggressive than usual.

Entities:  

Mesh:

Year:  1989        PMID: 2555094     DOI: 10.1016/0303-8467(89)90010-3

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  5 in total

Review 1.  A review of the therapy of paraneoplastic neurologic syndromes.

Authors:  A Das; F H Hochberg; S McNelis
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 2.  Neurologic complications of non-Hodgkin's lymphoma.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

3.  Immunoadsorption therapy for paraneoplastic syndromes.

Authors:  T T Batchelor; M Platten; F H Hochberg
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

4.  Human autoantibodies against desmoplakins in paraneoplastic pemphigus.

Authors:  J R Oursler; R S Labib; L Ariss-Abdo; T Burke; E J O'Keefe; G J Anhalt
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  Treatment of paraneoplastic cerebellar degeneration.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.